Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures
This article was originally published in The Pink Sheet Daily
Roche CEO Schwan also informed analysts that the company is not considering expanding its business into other areas such as a pharmaceutical generics or biosimilars.
You may also be interested in...
Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai
SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug
Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.
Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.